Susquehanna International Group LLP Reduces Stake in Prestige Consumer Healthcare Inc. $PBH

Susquehanna International Group LLP lessened its stake in shares of Prestige Consumer Healthcare Inc. (NYSE:PBH) by 84.7% during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 6,876 shares of the company’s stock after selling 38,086 shares during the period. Susquehanna International Group LLP’s holdings in Prestige Consumer Healthcare were worth $325,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also recently modified their holdings of PBH. UMB Bank n.a. increased its position in Prestige Consumer Healthcare by 110.1% during the fourth quarter. UMB Bank n.a. now owns 418 shares of the company’s stock worth $26,000 after purchasing an additional 219 shares during the last quarter. Barrow Hanley Mewhinney & Strauss LLC purchased a new position in Prestige Consumer Healthcare during the second quarter worth about $30,000. Versant Capital Management Inc boosted its holdings in Prestige Consumer Healthcare by 47.9% in the 2nd quarter. Versant Capital Management Inc now owns 726 shares of the company’s stock valued at $34,000 after purchasing an additional 235 shares during the last quarter. Caitong International Asset Management Co. Ltd boosted its holdings in Prestige Consumer Healthcare by 69.8% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 574 shares of the company’s stock valued at $35,000 after purchasing an additional 236 shares during the last quarter. Finally, Danske Bank A S acquired a new stake in shares of Prestige Consumer Healthcare during the 3rd quarter worth approximately $37,000. Institutional investors and hedge funds own 99.95% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms recently commented on PBH. Oppenheimer cut Prestige Consumer Healthcare from an “outperform” rating to a “market perform” rating in a report on Thursday, May 14th. Canaccord Genuity Group cut their target price on Prestige Consumer Healthcare from $86.00 to $72.00 and set a “buy” rating for the company in a research note on Friday, May 15th. Zacks Research upgraded Prestige Consumer Healthcare from a “strong sell” rating to a “hold” rating in a research report on Monday, August 10th. Finally, Weiss Ratings lowered Prestige Consumer Healthcare from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Thursday, June 25th. Two investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $70.75.

Prestige Consumer Healthcare Trading Up 2.1%

NYSE PBH opened at $52.85 on Wednesday. The company has a debt-to-equity ratio of 1.06, a quick ratio of 1.99 and a current ratio of 3.23. The firm has a market cap of $2.50 billion, a price-to-earnings ratio of 14.80, a PEG ratio of 1.62 and a beta of 0.33. The firm has a 50 day simple moving average of $50.48 and a 200-day simple moving average of $54.35. Prestige Consumer Healthcare Inc. has a one year low of $42.62 and a one year high of $71.07.

Prestige Consumer Healthcare (NYSE:PBH) last posted its quarterly earnings results on Thursday, August 6th. The company reported $0.98 EPS for the quarter, topping the consensus estimate of $0.89 by $0.09. Prestige Consumer Healthcare had a net margin of 15.57% and a return on equity of 11.39%. The business had revenue of $265.71 million during the quarter, compared to the consensus estimate of $253.02 million. During the same quarter in the previous year, the firm posted $0.90 earnings per share. The company’s quarterly revenue was up 6.5% compared to the same quarter last year. Prestige Consumer Healthcare has set its FY 2027 guidance at 4.550-4.650 EPS. Equities research analysts anticipate that Prestige Consumer Healthcare Inc. will post 4.56 EPS for the current fiscal year.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare, Inc is a leading manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company focuses on developing, acquiring and commercializing a diverse portfolio of non-prescription remedies designed to address common consumer health needs, including pain relief, cold and cough, digestive health, eye care, skin care and women’s health.

Key brands in Prestige’s portfolio include Clear Eyes (eye health), Carmex (lip care), Chloraseptic (sore throat relief), Dramamine (motion sickness), Rolaids (antacid), Monistat (women’s health), BC Powder (pain relief), Little Remedies (pediatric cold and gas relief) and TheraTears (dry eye therapy).